{"name": "TIA Prevention - Ulcer Prevention - Osteoporosis","decisional_state": "chosenState","workflow_state": "startedState","node_type": "task_node","children": [{"name": "TIA Prevention","source": "Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack, 2014, Stroke, p. 2198. \nFound at https:\/\/drive.google.com\/file\/d\/1sNM7HjUuM18_2jLba_35SYZtUrDBlkSC\/view?usp=sharing","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Antiplatelet treatment","description": "1. For patients with noncardioembolic ischemic stroke or TIA, the use of antiplatelet agents rather than oral anticoagulation is recommended to reduce the risk of recurrent stroke and other cardiovascular events (Class I; Level of Evidence A).\n4. The selection of an antiplatelet agent should be individualized on the basis of patient risk factor profiles, cost, tolerance, relative known efficacy of the agents, and other clinical characteristics (Class I; Level of Evidence C).","node_type": "decision_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Clopidogrel monotherapy","description": "3. Clopidogrel (75 mg) monotherapy is a reasonable option for secondary prevention of stroke in place of aspirin or combination aspirin\/dipyridamole (Class IIa; Level of Evidence B). This recommendation also applies to patients who are allergic to aspirin.","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "notChosenState","condition": "option3"},{"name": "Aspirin and dipyridamole","description": "2. Aspirin (50\u2013325 mg\/d) monotherapy (Class I; Level of Evidence A) or the combination of aspirin 25 mg and extended-release dipyridamole 200 mg twice daily (Class I; Level of Evidence B) is indicated as initial therapy after TIA or ischemic stroke for prevention of future stroke. (Revised recommendation)","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "notChosenState","condition": "option2"},{"name": "Aspirin monotherapy","description": "2. Aspirin (50\u2013325 mg\/d) monotherapy (Class I; Level of Evidence A) or the combination of aspirin 25 mg and extended-release dipyridamole 200 mg twice daily (Class I; Level of Evidence B) is indicated as initial therapy after TIA or ischemic stroke for prevention of future stroke. (Revised recommendation)","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","condition": "option1"}]}]},{"name": "Ulcer Prevention","source": "Management of Patients with Ulcer Bleeding, 2012, American Journal of Gastroenterology, p. 3. \nFound at https:\/\/drive.google.com\/file\/d\/1sK3dPAYfhQkumQ44DvTKN9s7swJ-6xKe\/view?usp=sharing","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Type of prevention","node_type": "decision_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Primary prevention (no CVD)","description": "If given for primary prevention (i.e., no established cardiovascular disease), anti-platelet therapy likely should not be resumed in most patients (Conditional recommendation).","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "notChosenState","condition": "no CVD","children": [{"name": "Suspend aspirin","description": "If given for primary prevention (i.e., no established cardiovascular disease), anti-platelet therapy likely should not be resumed in most patients (Conditional recommendation).","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState"}]},{"name": "Secondary prevention (CVD)","description": "If given for secondary prevention (i.e., established cardiovascular disease) then aspirin should be resumed as soon as possible after bleeding ceases in most patients: ideally within 1 \u2013 3 days and certainly within 7 days. Long-term daily PPI therapy should also be provided.","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","condition": "CVD","children": [{"name": "Resume Aspirin","description": "If given for secondary prevention (i.e., established cardiovascular disease) then aspirin should be resumed as soon as possible after bleeding ceases in most patients: ideally within 1 \u2013 3 days and certainly within 7 days.","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState"},{"name": "Add PPI","description": "If given for secondary prevention (i.e., established cardiovascular disease) [..] Long-term daily PPI therapy should also be provided.","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState"}]}]}]},{"name": "Osteoporosis","source": "American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. 2016, Endocrine Practice. pp. 3,6,14,15. \nFound at https:\/\/drive.google.com\/file\/d\/1sK-0Bw_4DAyfO3nPqXX-1ScZ5VsSNNtL\/view?usp=sharing","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Diagnose Osteoporosis","node_type": "task_node","workflow_state": "startedState","decisional_state": "chosenState","children": [{"name": "Detailed history and physical exam","description": "A detailed history, physical exam, and [..] should be included in the initial evaluation for osteoporosis (Grade B; BEL 2).","node_type": "task_node","workflow_state": "completedState","decisional_state": "chosenState"},{"name": "FRAX assessment","description": "[..] and clinical fracture risk assessment with the Fracture Risk Assessment Tool (FRAX\u00AE) should be included in the initial evaluation for osteoporosis (Grade B; BEL 2).","node_type": "task_node","workflow_state": "completedState","decisional_state": "chosenState"},{"name": "BMD assessment","description": "R3. Consider bone mineral density (BMD) testing based on clinical fracture risk profile (Grade B; BEL 2).\nR4. When BMD is measured, axial dual-energy X-ray absorptiometry (DXA) measurement (spine and hip) should be used (Grade B; BEL 2).","node_type": "task_node","workflow_state": "completedState","decisional_state": "chosenState"},{"name": "Diagnosis outcome","node_type": "decision_node","workflow_state": "startedState","decisional_state": "chosenState","after": "Diagnose Osteoporosis","children": [{"name": "Halt","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "notChosenState","condition": "negative"},{"name": "Osteoporosis treatment","node_type": "task_node","workflow_state": "activeState","decisional_state": "chosenState","condition": "positive","children": [{"name": "Decide drug treatment","description": "Patients with high risk for future fractures (>=20%) should be given medications to reduce the risk.","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"name": "Drugs to reduce fractures","description": "R23. Approved agents with efficacy to reduce hip, non-vertebral, and spine fractures including alendronate, risedronate, zoledronic acid, and denosumab are appropriate as initial therapy for most patients at high risk of fracture (Grade A; BEL 1).","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "high fracture risk"}]},{"name": "Suspend contributing factors","description": "If the patient is taking a drug (e.g., PPI) known to be a contributing factor to osteoporosis, consider stopping that drug.","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState"}]}]}]}]}]}